Evaluating the Anti-Osteoarthritis Potential of Standardized Boswellia serrata Gum Resin Extract in Alleviating Knee Joint Pathology and Inflammation in Osteoarthritis-Induced Models

• Published in: International journal of molecular sciences 2024-03, Vol.25 (6), p.3218
• Main Authors: Choi, Yean-Jung, Jung, Jae In, Bae, Jaewoo, Lee, Jae Kyoung, Kim, Eun Ji
• Format: Article
• Language: English
• Subjects: aggrecan; Aggrecans - metabolism; Animals; Arthritis; Boswellia - metabolism; Boswellia serrata; Cartilage; Cartilage, Articular - metabolism; Cytokines; Disease Models, Animal; Humans; Inflammation - metabolism; Interleukin-6 - metabolism; Iodoacetic Acid - adverse effects; Knee; Knee Joint - pathology; monosodium iodoacetate; Osteoarthritis; Osteoarthritis - metabolism; Quality of Life; Rats; RNA, Messenger - metabolism; Tumor Necrosis Factor-alpha - metabolism; Tumor necrosis factor-TNF; type II collagen
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25063218

Osteoarthritis is a widespread chronic degenerative disease marked by the deterioration of articular cartilage, modifications in subchondral bone, and a spectrum of symptoms, including pain, stiffness, and disability. Ultimately, this condition impairs the patient's quality of life. This study aimed to evaluate the therapeutic efficacy of standardized gum resin extract (BSRE) in a rat model of monosodium iodoacetate (MIA)-induced osteoarthritis. A total of 60 rats were allocated into six groups: normal control group (NC), osteoarthritis control (injected with MIA, OC), O + B50 (injected with MIA and treated with 50 mg/kg body weight (BW) BSRE), O + B75 (injected with MIA and treated with 75 mg/kg BW BSRE), O + B100 (injected with MIA and treated with 100 mg/kg BW BSRE), and O + M (injected with MIA and treated with 150 mg/kg BW methyl sulfonyl methane). Several parameters, including knee joint swelling, histopathological changes, and the expression of collagen type II alpha 1 (COL2A1) and aggrecan, were comprehensively assessed. Concurrently, the serum levels and mRNA expression of inflammatory mediators, cytokines, and matrix metalloproteinases (MMPs) were analyzed in both the serum and knee joint synovium. The results demonstrated that BSRE significantly mitigated knee joint swelling, cartilage destruction, and tissue deformation. Notably, BSRE administration markedly upregulated the expression of COL2A1 and aggrecan while concurrently reducing levels of nitric oxide, prostaglandin E2, leukotriene B4, interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Furthermore, a substantial decrease was observed in the mRNA expression of inducible nitric oxide synthase, cyclooxygenase-2, 5-lipoxygenase, IL-6, TNF-α and MMP-3 and -13, thereby indicating promising therapeutic implications for osteoarthritis. In conclusion, BSRE exhibited anti-inflammatory properties and inhibited cartilage matrix degradation in a rat model of MIA-induced osteoarthritis, with the O + B100 group showing significant reductions in swelling and notable improvements in joint cartilage damage. These findings illuminate the preventive and therapeutic potential of BSRE for osteoarthritis treatment, emphasizing the criticality of exhaustive evaluation of novel compounds.